StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

Equities research analysts at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 2.4 %

Shares of Evoke Pharma stock opened at $4.41 on Tuesday. The stock’s fifty day moving average is $4.72 and its two-hundred day moving average is $5.14. Evoke Pharma has a 52 week low of $3.54 and a 52 week high of $12.84. The company has a market capitalization of $6.57 million, a PE ratio of -0.40 and a beta of 0.16.

Institutional Trading of Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent SEC filing.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.